Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Operating Cash Flow

Cash generated by the company's core business operations during the period.

Alto Neuroscience, Inc.NYSE: ANRO

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow growth accelerates

Q1 FY2026 operating cash flow of $27.09M (cash outflow) rose 63.6% year over year, ahead of the +17.6% change in trailing-twelve-month operating cash flow. Sequentially, it rose 135.2% from the prior quarter. Over 3 fiscal years it compounded at +36.4% a year.

Context

  • Operating cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +63.6% holds above the trailing-twelve-month pace of +17.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$27.09M+135.2% QoQ
Last fiscal yearDec 2025
-$51.77M+9.2% YoY
LTMMar 2026
-$62.3M+17.6% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+63.6%——
1 year+9.2%——
3-year CAGR+36.4%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(51.77M) USD
Year-over-year change
-9.2%

Operating Cash Flow vs competitors

How ANRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.6% is the 5th highest of 9, against a peer median of +29.0%.
  • Over three fiscal years its annual growth of +36.4% compares with a peer median of +3.8%.
ANRO Competitors
Operating Cash Flow for ANRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DBVTDBV Technologies S.A.LTM Mar 2026$150.61M USD+68.4%+29.6%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$131.28M USD+51.1%+60.1%—
KRROKorro Bio, Inc.LTM Mar 2026$70.18M USD+12.1%+13.6%1826.7%
ACIUAC Immune S.A.LTM Dec 2025CHF 69.2M CHF-205.1%-3.5%1936.8%
SLNSilence Therapeutics plcLTM Mar 2026$65.57M USD—+3.0%7115.1%
ANROAlto Neuroscience, Inc.LTM Mar 2026$62.3M USD+17.6%+36.4%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$57.17M USD+46.0%+40.1%—
CLLSCellectis S.A.LTM Mar 2026$37.91M USD-230.1%-22.9%55.7%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$26.68M USD—+3.8%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$25.99M USD-43.1%-16.2%—
AMRNAmarin Corporation plcLTM Mar 2026$25.51M USD+182.6%—11.9%
Peer median (excluding ANRO) —+29.0%+3.8%1826.7%

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Depreciation & Amortization145K342K373K502K661K
Deferred Income Tax00000
Stock-Based Compensation227K1.76M2.89M7.63M8.11M
Change in Working Capital(572K)4.58M(698K)4.06M33K
Accounts Receivables(1.29M)1.16M325K00
Inventory00000
Accounts Payables458K1.01M(632K)516K221K
Other Working Capital255K2.42M(391K)3.54M(188K)
Other Non-Cash Items125K632K291K1.81M2.67M
Operating Cash Flow(9.26M)(20.39M)(33.45M)(47.42M)(51.77M)
Capital Expenditures(680K)(732K)(470K)(2.08M)(24K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(680K)(732K)(470K)(2.08M)(24K)
Debt Repayment09.83M01.25M9.48M
Common Stock Issued7K43K181K137.58M50.7M
Common Stock Repurchased0000(167K)
Dividends Paid00000
Other Financing Activities(205K)(341K)(2.05M)(3.14M)67K
Financing Cash Flow31.69M43.79M68.13M135.69M60.08M
Effect of Forex Changes(50K)(24K)(8K)(11K)(30K)
Net Change in Cash21.7M22.64M34.2M86.18M8.26M
Free Cash Flow(9.94M)(21.13M)(33.92M)(49.5M)(51.79M)

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.